[3]Hurvitz SA,Hegg R,Chung WP,et al.Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer:updated results from DESTINY-Breast03,a randomised,open-label,phase 3 trial.Lancet.2023 Jan 14;401(10371):105-117. [4]Tarantino P,Curigliano G,Parson...
[19] Updated analysis of DESTINY-Gastric02: A phase II single-arm trial of trastuzumab deruxtecan (T-DXd) in western patients (Pts) with HER2-positive (HER2+) unresectable/metastatic gastric/gastroesophageal junction (GEJ) cancer who...
Bidard FC, Champion L, Duong P, Dercle L, Seban RD. PET/CT and SPECT/CT Imaging of HER2-Positive Breast Cancer. J Clin Med. 2023 Jul 25;12(15):4882. doi: 10.3390/jcm12154882. PMID: 37568284; PMCID: PMC10419459
unresectable, or metastatic HER2-positive breast cancer: a systematic review and network meta-analysis. Breast Cancer Res Treat. 2020;180(3):597-609.
参考文献: Marra, Antonio et al. “Management of patients with advanced-stage HER2-positive breast cancer: current evidence and future perspectives.” Nature reviews. Clinical oncology vol. 21,3 (2024): 185-202. doi:10.1038/s41571-023-00849-9...
[2] Hurvitz SA, Hegg R, Chung WP, et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. Lancet. 2023 Jan 14;401(10371):105-117. ...
[3]Do TILs predict benefits from trastuzumab therapy for HER2 positive breast cancer? Meta-analysis of individual patient data from 4097 women in 5 trials. 2023 ASCO Abstract 508. [4]Lancet Oncol. 22(8),1139-50,2021. 作者:钱多乐;编辑:HUan; ...
[8]Sara A. Hurvitz, et al. A pooled analysis of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC) with brain metastases (BMs) from DESTINY-Breast (DB) -01, -02, and -03. 2023 ESMO 377O....
[9]Escrivá-de-RomaníS,ArumíM,Bellet M,et al.HER2-positive breast cancer:current and new therapeutic strategies.Breast.2018;39:80–88. [10]Whitehead I,IrwinG W,Bannon F,et al.The NeST(neoadjuvant systemic therapy in breast cancer)study:National Practice Questionnaire of United Kingdom multi...
3、Kenichi Inoue,et al.“Long-term outcomes of neoadjuvant trastuzumab emtansine+pertuzumab(T-DM1+P)and docetaxel+carboplatin+trastuzumab+pertuzumab(TCbHP)for HER2-positive primary breast cancer:JBCRG20 study(Neo-peaks).”2023 ESMO BC Abstract 125MO. ...